Bulletin
Investor Alert

New York Markets After Hours

Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 18, 2022, 4:53 p.m.

/zigman2/quotes/207821052/composite

$

46.94

Change

0.00 0.00%

Volume

Volume 16,886

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Today's close

$ 48.33

$ 46.94

Change

-1.39 -2.88%

Day low

Day high

$45.60

$49.09

Open

52 week low

52 week high

$38.85

$202.73

Open

David Lebwohl

Presently, David Lebwohl holds the position of Chief Medical Officer & Executive Vice President at Intellia Therapeutics, Inc. He is also Member of American Society of Clinical Oncology.

In the past Dr. Lebwohl occupied the position of Chief Medical Officer of Semma Therapeutics, Inc. and Senior Vice President for Novartis Pharmaceuticals Corp.

David Lebwohl received an undergraduate degree from Harvard College and a doctorate from Yale School of Medicine.

Transactions

Date Shares Transaction Value
03/01/2022 13,816   Award at $0 per share. 0
01/01/2022 1,051   Disposition at $112.24 per share. 117,965
01/01/2022 3,187   Derivative/Non-derivative trans. at $0 per share. 0
11/05/2021 200   Disposition at $135.34 per share. 27,068
11/05/2021 548   Disposition at $134.07 per share. 73,471
11/05/2021 452   Disposition at $132.62 per share. 59,945
11/05/2021 1,200   Disposition at $131.71 per share. 158,052
11/05/2021 2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
10/14/2021 250   Disposition at $130.47 per share. 32,618
10/14/2021 525   Disposition at $129.83 per share. 68,161
10/14/2021 225   Disposition at $129.01 per share. 29,028
10/14/2021 849   Disposition at $127.81 per share. 108,511
10/14/2021 551   Disposition at $126.92 per share. 69,933
10/14/2021 2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
09/24/2021 7,923   Derivative/Non-derivative trans. at $12.62 per share. 99,988
09/21/2021 2,400   Disposition at $149.81 per share. 359,544
09/21/2021 2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
08/30/2021 150   Disposition at $160.1 per share. 24,015
08/30/2021 1,100   Disposition at $159.19 per share. 175,109
08/30/2021 250   Disposition at $157.6 per share. 39,400
08/30/2021 700   Disposition at $156.7 per share. 109,690
08/30/2021 200   Disposition at $155.43 per share. 31,086
08/30/2021 2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288
08/09/2021 2,400   Disposition at $164.05 per share. 393,720
08/09/2021 2,400   Derivative/Non-derivative trans. at $12.62 per share. 30,288

Officers and Executives

Dr. John M. Leonard
President, Chief Executive Officer & Director
Mr. Glenn Goddard
Treasurer, Chief Financial & Accounting Officer
Dr. Laura Sepp-Lorenzino
Chief Scientific Officer & Executive VP
Dr. Eliana Clark
Chief Technology Officer & Executive VP
Dr. David Lebwohl
Chief Medical Officer & Executive Vice President
Dr. Christine Foster
SVP-Business Development & Alliance Management
Mr. Derek Hicks
Chief Business Officer & Executive Vice President
Mr. Ian Karp
Senior Vice President-Corporate Communications
Ms. Marika St Amand
Chief Human Resources Officer
Mr. James Basta
Secretary, Executive VP & General Counsel
Dr. Frank A. G. M. Verwiel
Chairman
Mr. John Francis Crowley
Independent Director
Dr. Georgia Keresty
Independent Director
Ms. Muna Bhanji
Independent Director
Dr. Jean-Francois B. Formela
Independent Director
Ms. Caroline D. Dorsa
Independent Director
Dr. Jesse L. Goodman
Independent Director
Dr. Fred Ehrenkranz Cohen
Independent Director
Link to MarketWatch's Slice.